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Approximately 22,000new cases of ovarian cancerwill be diagnosed
in the United States in 2013 (American Cancer Society, 2013).
Cytoreductive surgery with adjuvant taxane and platinum based
chemotherapy has been established as the gold-standard treatment
(Bristow et al., 2002). 70–80% of women will present with advanced
disease at the time of diagnosis. Surgical debulking and adjuvant
chemotherapy can result in a complete clinical remission in 50% of
these patients. However, more than 70% of patients who respond to
initial therapy will recur (Leitao and Chi, 2009).
Incorporation of intraperitoneal (IP) delivery to intravenous (IV) de-
livery of chemotherapy for the treatment of optimally debulked ovarian
cancer has been well studied. IP plus IV chemotherapy has been shown
to improve overall survival in multiple large randomized clinical trials
when compared to systemic chemotherapy alone (Armstrong et al.,
2006; Alberts et al., 1996; Markman et al., 2001). Hyperthermic intra-
peritoneal chemotherapy (HIPEC) adds the beneﬁcial effects of hyper-
thermia by increasing drug permeability and metabolism of malignant
cells. HIPEC has been described for treatment of recurrent ovarian
cancer, however there is no general consensus regarding its efﬁcacy
(Chua et al., 2009; Fagotti et al., 2012).
Maximal cytoreductive effort has been expanded to include Video-
Assisted Thoracic Surgery (VATS) for the evaluation of disease spread.
VATS has been demonstrated to provide improved accuracy of surgical
staging without increasing signiﬁcant morbidity (Klar et al., 2012).⁎ Corresponding author.
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with pleural involvement of ovarian cancer has not, to our knowledge,
been previously investigated. Hyperthermic Intra-Thoracic Chemother-
apy (HITeC) after VATS debulking of disease is a novel technique that
exploits the established advantages of cytoreduction, intracavitary che-
motherapy, and hyperthermia. We present our experience with HITeC
in pre-treated patients with recurrent disease in the pleural cavity.
The primary objectives of this study were to assess the feasibility of
and morbidity associated with HITeC. The secondary objectives were
to evaluate the local control and disease recurrence.Methods
We reviewed the patients with recurrent ovarian cancer involving
the pleura treated with VATS and HITeC between July 2011 and June
2012. Each procedure was a joint effort between gynecologic oncolo-
gists and thoracic surgeons. HITeC was administered after all pleural
disease was resected to less than 5 mm. The regimens included:
Paclitaxel (135 mg/m2) + Cisplatin (80 mg/m2), Adriamycin
(15 mg/m2) + Cisplatin (80 mg/m2), or Paclitaxel (175 mg/m2) alone.
Each agent was prepared in 3 l of saline. The choice of chemotherapy
was dictated by the previous treatment response. VATS and tumor re-
section were performed by the thoracic surgeon. After the disease was
resected, right angle chest tubes were inserted through the inferior
VATS port sites. These chest tubes were then connected to the hyper-
thermia pump, and chemotherapy was perfused at an efﬂuent temper-
ature of 42 °C for 45 min (Fig. 1). When 2 agents were used, each drug
was perfused sequentially, with 1 l of saline ﬂushed in between. After
the completion of the heated chemotherapy infusion, the pleural cavity
was irrigated with 1–2 l of normal saline. The 2 right angle chest tubes
were then removed. A straight chest tube was then placed through
one of the incisions and left in place for post-operative management.
Chest tubes were removed prior to discharge from the hospital. Post-
operative management and discharge home were at the discretion of
the treating physicians.
This retrospective case series was approved by the Institutional
Review Board of University Hospitals Case Medical Center. Data for
each patient was abstracted from inpatient and outpatient medical re-
cords. Intra-operative and post-operative variables, 30-day morbidity,
local control, and disease recurrence were reported. The data was ana-
lyzed primarily with descriptive statistics. The results are reported asthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Patient demographics and treatment history.
Patient Age at time
of HITeC (years)
Original
FIGO stage
Tumor histology # Prior chemotherapy
regimens
# Prior chemotherapy
cycles
1 44 IV Undifferentiated with transitional cell, papillary serous, and clear cell components 1 6
2 61 IIIB High grade papillary serous 3 18
3 67 IIIC High grade papillary serous 1 8
4 67 IV High grade papillary serous 7 30
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non-normal.
Results
Four patients with recurrent papillary serous ovarian cancer involv-
ing the pleura underwent VATS and HITeC. Two patients had one tho-
racic cavity treated and two had bilateral sequential procedures, with
the second hemithorax treated 4 weeks after the ﬁrst. A total of 6 tho-
racic cavities were thus treated.
Demographic and history details are listed in Table 1. Median age
was 64 years (44–67). All patients had a GOG performance status of
0–1. They had a median of 2 (1–7) prior chemotherapy regimens and
of 13 (6–30) prior chemotherapy cycles. All patients had recurrent dis-
ease in the pelvis, abdomen, and chest, andwere being treatedwith sys-
temic chemotherapy prior to VATS/HITeC. This was the ﬁrst recurrence
for two of the patients. One patient had completed the initial treatment
with optimal surgical debulking followed by 6 cycles of IV/IP cisplatin
and taxol. She was diagnosed with recurrence more than 1 year after
completion of this initial therapy. The other patient being treated for
the ﬁrst recurrence presented initially with metastatic disease in the
spine. She completed systemic chemotherapy and spine radiation
4 months prior to her recurrence. The other two patients had received
more than one prior chemotherapy regimen.
Table 2 lists intra-operative details. No intra-operative complications
were noted. Median length of hospital stay was 2 days (2–6). One pa-
tient required admission to the Surgical Intensive Care Unit post-
operatively for acidosis, which resolved with supportive care. No other
peri-operative complications were identiﬁed, and there were no
re-admissions within the 30-day post-operative period. All the patients
received systemic chemotherapy within 6 weeks of VATS/HITeC.
Themean pre-operative and post-operative CA-125 levels were 42.8
(19.3–71.5) and 15.5 (6.9–29.6). Long-term local control, as measured
by imaging and CA-125, was observed in all patients. Disease free inter-
val in the treated thoracic cavities ranged from 6 to 12 months. Two pa-
tients developed chest wall recurrences at VATS port sites – one patient
12 months after and the other patient 17 months after VATS/HITeC.
Both were successfully surgically excised. Median followup at the time
of this manuscript preparation was 13.5 months (range 9–18). 3 of
the 4 patients received additional systemic chemotherapy after HITEC.
At the time of this writing, all patients who underwent VATS/HITeC
are alive. Since VATS/HITeC, subjects have received a median of 3 (1–4)
different systemic chemotherapy regimens with a median of 12 (8–20)
cycles. Three patients are being treated for extra-thoracic recurrence
with stable chest disease. The 4th patient progressed in her chest
following 18 months of stable thoracic disease.
Discussion
Themajority of womenwith advanced epithelial ovarian cancer will
develop recurrent disease, and survival for 2 or more years following
initial relapse is not uncommon. Secondary surgical cytoreduction can
be considered for patients with recurrent ovarian carcinoma (Chi
et al., 2006). Typically, this is limited to disease in the abdomen or pelvis,
although some patients are candidates for resection of pleural disease.The concept of directly instilling chemotherapy into the chest cavity
takes advantage of the established beneﬁts of intraperitoneal chemo-
therapy in optimally debulked patients.
The treatment of recurrent ovarian cancer often includes a
multimodality approach and a combination of chemotherapy, surgery,
and radiation.Options can quickly become limited, especially in patients
with platinum resistant disease or in those with multiple prior thera-
pies. In this series of patients with recurrent ovarian cancer involving
the pleural cavity, we demonstrate that the technique of VATS/HITeC
is technically feasible and is well-tolerated without signiﬁcant morbid-
ity. Despite being heavily pre-treated, patients who underwent HITeC
appeared to have excellent local control. One limitation of our study is
the variety of chemotherapeutic regimens that were employed. A single
regimen has not been identiﬁed as optimal, and choice of agent should
be patient speciﬁc. Patients with platinum sensitive disease are candi-
dates for the administration of platinum containing regimens directly
into the thoracic cavity. Those that are platinum resistant may beneﬁt
from alternative agents. Future studies with larger numbers of patients
divided into subgroups based on platinum response will be necessary.
Other limitations include the small number of included patients and
the retrospective nature of the analysis. HITeC is a promising new tech-
nique for the management of recurrent ovarian cancer and warrants
further study.
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